Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA IT Systems In Senate Appropriators’ Crosshairs

This article was originally published in The Tan Sheet

Executive Summary

The Senate Appropriations Committee approves a $3.9 billion spending plan for the agency in fiscal 2013, providing a $12.5 million boost in direct funding over President Obama’s proposed budget, with the extra funds slated for the food and animal drug programs.

Advertisement

Related Content

FDA Faces More Tech Hurdles After Clearing AERs Backlog, And Congress Is Watching
FDA Faces More Tech Hurdles After Clearing AERs Backlog, And Congress Is Watching
FDA Seeks New Chief Information Officer In Privacy And Security Overhaul
FDA Seeks New Chief Information Officer In Privacy And Security Overhaul
FDA Chief Operating Officer Brings IT Experience From CDC, Sodexo
FDA Appropriators Discuss Ending The Food & Drug Administration
Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization
Sanofi-Aventis offer

Topics

Advertisement
UsernamePublicRestriction

Register

PS105749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel